Retatrutide Phase 3 Results: What the Data Actually Means
Summary
Hosts Dr. Spencer Nadolsky and Dr. Carl interview nurse practitioner David White, a participant in the TRIUMPH 1 trial, about retatrutide, a triple GIP/GLP-1/glucagon agonist. They discuss White’s personal weight loss experience and review Phase 3 data showing superior efficacy for obesity, type 2 diabetes, knee osteoarthritis, and sleep apnea compared to existing therapies. The episode also covers side effects, clinical switching strategies, and future cardiovascular outcome trials.
Topics discussed
Introduction and guest David White's background
Mechanisms of Retatrutide: GLP-1, GIP, and Glucagon
David's personal trial experience and side effects
Phase 3 obesity trial results and weight loss data
Cardiometabolic benefits and adverse events
Type 2 diabetes trial outcomes and A1C reduction
Clinical switching strategies from other GLP-1s
FDA classification, cost concerns, and future trials
Listen ad-free on Castria